Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients

被引:96
|
作者
Fisher, Cynthia E. [1 ,2 ]
Knudsen, Janine L. [1 ]
Lease, Erika D. [1 ,3 ]
Jerome, Keith R. [2 ,4 ]
Rakita, Robert M. [1 ]
Boeckh, Michael [1 ,2 ]
Limaye, Ajit P. [1 ]
机构
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA
[4] Univ Washington, Dept Lab Med, Virol Div, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
cytomegalovirus; solid organ transplant; ganciclovir resistance; risk factors; outcomes; RAPID DETECTION; DISEASE; EMERGENCE; PROPHYLAXIS; FOSCARNET; SAMPLES; IMPACT; UL97; ERA;
D O I
10.1093/cid/cix259
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important problem in solid organ transplant (SOT) recipients. Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable specifically to ganciclovir resistance appropriately be determined. Methods. We performed a retrospective, case-control (1: 3) study of SOT recipients with genotypically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation. We used chi(2) (categorical) and Mann-Whitney (continuous) tests to determine predisposing factors and morbidity attributable to resistance, and Kaplan-Meier plots to analyze survival differences. Results. The rate of ganR-CMV was 1% (37/3467) overall and 4.1% (32/777) among CMV donor-positive, recipient-negative patients, and was stable over the study period. GanR-CMV was associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P<.001). Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance testing threshold), and all non-lung recipients had received = 90 days (median, 160 [range, 90-284 days]) prior to diagnosis of ganR-CMV. GanR-CMV was associated with higher mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decreased renal function (42% vs 19%, P = .008) by 3 months after diagnosis. Conclusions. GanR-CMV is associated with longer prior antiviral duration and higher attributable morbidity and mortality than ganS-CMV. Upcoming revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug exposure to guide rational ganR-CMV testing in SOT recipients. Improved strategies for prevention and treatment of ganR-CMV are warranted.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 50 条
  • [1] Ganciclovir-resistant cytomegalovirus in organ transplant recipients
    Limaye, AP
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) : 866 - 872
  • [2] Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients
    Mylonakis, E
    Kallas, WM
    Fishman, JA
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (10) : 1337 - 1341
  • [3] Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature
    Rolling, Katherine E.
    Jorgenson, Margaret R.
    Descourouez, Jillian L.
    Mandelbrot, Didier A.
    Redfield, Robert R.
    Smith, Jeannina A.
    PHARMACOTHERAPY, 2017, 37 (10): : 1258 - 1271
  • [4] Viral load response to therapy in ganciclovir-resistant and ganciclovir-sensitive cytomegalovirus infection in solid organ transplant recipients
    Chemaly, RF
    Yen-Lieberman, B
    Isada, CM
    Longworth, D
    Secic, M
    Kohn, D
    Gordon, SM
    Avery, RK
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1163 - 1163
  • [5] Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection
    Avery, Robin K.
    Arav-Boger, Ravit
    Marr, Kieren A.
    Kraus, Edward
    Shoham, Shmuel
    Lees, Laura
    Trollinger, Brandon
    Shah, Pali
    Ambinder, Rich
    Neofytos, Dionysios
    Ostrander, Darin
    Forman, Michael
    Valsamakis, Alexandra
    TRANSPLANTATION, 2016, 100 (10) : E74 - E80
  • [6] Outcomes Associated with Ganciclovir-Resistant Cytomegalovirus in Lung Transplant Recipients
    Hammad, S.
    Shah, L.
    Restivo, M.
    Robbins, H.
    Scheffert, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S309 - S310
  • [7] Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study
    Young, P. G.
    Rubin, J.
    Angarone, M.
    Flaherty, J.
    Penugonda, S.
    Stosor, V.
    Ison, M. G.
    TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (03) : 390 - 395
  • [8] Emergence of ganciclovir-resistant cytomegalovirus disease among solid organ transplant (SOT) recipients.
    Limaye, AP
    Corey, L
    Koelle, DM
    Davis, CL
    Boeckh, M
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A39 - A39
  • [9] Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients
    Bhorade, SM
    Lurain, NS
    Jordan, A
    Leischner, J
    Villanueva, J
    Durazo, R
    Creech, S
    Vigneswaran, WT
    Garrity, ER
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (12): : 1274 - 1282
  • [10] Characteristics of Ganciclovir Resistant Cytomegalovirus in Solid Organ Transplant Recipients
    Zuberi, Muhammad
    Hamandi, Bassem
    Ingram, Sara
    Munyal, Dipika
    Yi, Teresa
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2007, 60 : 62 - 62